TP53 and laryngotracheoesophageal cleft: Metastatic disease was evaluated as M1 in 11, M2 in 17, and M3 in 49 while 12 patients had other high-risk features (LC/A histology in 9, LC/A histology and MYC amplification in 1, and TP53 mutation in the remaining 2 patients) and no metastatic disease (M0).